All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure) and who are willing to participate in the study would be enrolled. After performing baseline biochemical tests, patients will undergo transjugular liver biopsy (TJLB), HVPG (Hepatic Venous Pressure Gradient), Circulating CD34 cells, Bone marrow aspiration and biopsy (Histopathological and immunohistochemical examination will be done).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
14
Institute of liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Transplant free survival in both groups
Time frame: 1 year
Quantitative assessment of CD34 positive cells in serum in both groups.
On Immunohistochemistry of liver biopsy tissue,quantification of + ve CD34 cells will be done
Time frame: 1 year
Quantitative assessment of CD34 positive cells in liver biopsy samples in both groups.
On Immunohistochemistry of liver biopsy tissue,quantification of + ve CD34 cells will be done
Time frame: 1 year
Reduction in liver disease severity indices like CTP (Child-Turcotte-Pugh) by more than one point in both groups.
Time frame: 1 year
Reduction in liver disease severity indices like MELD Na ((Model for End Stage liver disease) by more than 2 points in both groups.
Time frame: 1 year
Development of new onset complications such as hepatic encephalopathy in both groups.
Time frame: 1 year
Development of new onset complications such as hepatorenal syndrome in both groups.
Time frame: 1 year
Development of new onset complications such as sepsis in both groups.
Time frame: 1 year
Development of new onset complications such as Hepatocellular carcinoma (HCC).
Time frame: 1 year
Total number of CD34 positive cells in histopathological examination of bone marrow in both groups
Time frame: 1 year
No of adverse events in both groups
Time frame: 1 year
Reduction in HVPG (Hepatic Venous Pressure Gradient) in both groups
Time frame: 1 year
Reduction in HBV DNA level in both groups.
Time frame: 1 year
Number of patients who will restart alcohol abuse during the follow up period in both groups.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.